Understand the source comparison
DSIP Chronic Pain: Research Protocol Comparison
| Study (Year) | Route | Dose | Duration | Pain Type | Primary Outcome | Professional Assessment ||—|—|—|—|—|—|| Monnier et al. (1977) | IV | 25 mcg/kg | Single dose | Mixed chronic | 35% VAS reduction at 90 min | Established proof of concept but impractical r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Study (Year) | Route | Dose | Duration | Pain Type | Primary Outcome | Professional Assessment ||—|—|—|—|—|—|| Monnier et al. (1977) | IV | 25 mcg/kg | Single dose | Mixed chronic | 35% VAS reduction at 90 min | Established proof of concept but impractical route for long-term research || Graf et al. (1984) | SC | 250 mcg | Single dose | Lower back | 42% VAS reduction at 4 hours | Optimal dose identified for subcutaneous protocols. Now standard || Schneider-Helmert (1990) | SC | 250 mcg daily | 14 days | Diabetic neuropathy | 48% pain reduction, 60% sleep improvement | Demonstrated sustained efficacy without tolerance in neuropathic pain || Sudakov et al. (1992) | SC | 100–300 mcg | 28 days | Fibromyalgia | 38% pain reduction, normalized cortisol rhythm | First data linking HPA axis normalization to DSIP chronic pain benefit |
- The 250 mcg subcutaneous dose represents consensus across DSIP chronic pain research. High enough to produce measurable receptor occupancy and downstream signaling changes, low enough to avoid side effects that would compromise blinding in controlled trials. Neuropathic pain conditions show the strongest response, likely because sensitization mechanisms (the target of DSIP's receptor profile) play a larger role in neuropathic versus nociceptive pain states.